SCHEMBL7250815

SCHEMBL7250815

c1ccc(CCC(c2ccccc2)N2CCCCC2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 2/20 0.71
CYP1A2 P05177 6/20 0.70
CYP2C19 P33261 6/20 0.70
CYP3A4 P08684 5/20 0.70
CYP2D6 P10635 5/20 0.70
TSHR P16473 1/20 0.70
CYP2C9 P11712 5/20 0.53
HPGD P15428 1/20 0.53
MAPK1 P28482 1/20 0.53
KCNA5 P22460 4/20 0.52
KCNH2 Q12809 4/20 0.52
KCNE1 P15382 1/20 0.52
HRH3 Q9Y5N1 1/20 0.50
SLC6A2 P23975 1/20 0.49
SIGMAR1 Q99720 1/20 0.49
CCR3 P51677 1/20 0.48
ALDH1A1 P00352 1/20 0.47
SLC6A3 Q01959 1/20 0.46
GAA P10253 1/20 0.44
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6676554 0.89 SLC6A4 (0.58) SLC6A4CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL5444533 0.83 SLC6A4 (1.00) SLC6A4CYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL16226720 0.83 SLC6A4 (0.68) SLC6A4CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL3715253 0.82 CYP1A2 (1.00) SLC6A4CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL5755490 0.81 CYP1A2 (0.62) SLC6A4CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL113896 0.81 CYP1A2 (0.62) SLC6A4CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL6604030 0.81 CYP1A2 (0.62) SLC6A4CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL10601133 0.81 CYP1A2 (0.62) SLC6A4CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL9366741 0.80 CYP1A2 (0.96) SLC6A4CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL10366446 0.79 SLC6A4 (0.51) SLC6A4CYP1A2CYP2C19CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6534525-B1 Method of using 2- substituted piperidine analogs as selectively active antagonist of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, WARNER-LAMBERT & COMPANY 2003-03-18 US disclosed
US-6124317-A ACTIVE DRUG TREATING STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMIOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE HEADACHES, CHRONIC PAIN, GLAUCOMA, CMV RETINITIS, PSYCHOSIS WARNER-LAMBERT COMPANY (US) 2000-09-26 US disclosed
WO-1997023215-A1 2-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1997-07-03 WO disclosed